Multimodality Therapy for Limited-Stage Small-Cell Lung Cancer | Zendy

Daniel Almquist | Zendy; Kailash Mosalpuria | Zendy; Apar Kishor Ganti | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Multimodality Therapy for Limited-Stage Small-Cell Lung Cancer

Author(s) -

Daniel Almquist,

Kailash Mosalpuria,

Apar Kishor Ganti

Publication year - 2016

Publication title -

journal of oncology practice

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.555

H-Index - 60

eISSN - 1935-469X

pISSN - 1554-7477

DOI - 10.1200/jop.2015.009068

Subject(s) - medicine , radiation therapy , stage (stratigraphy) , prophylactic cranial irradiation , disease , small cell lung carcinoma , chemotherapy , oncology , lung cancer , small cell carcinoma , paleontology , myocardial infarction , conventional pci , biology

Limited-stage small-cell lung cancer (SCLC) occurs in only one third of patients with SCLC, but it is potentially curable. Combined-modality therapy (chemotherapy and radiotherapy) has long been the mainstay of therapy for this condition, but more recent data suggest a role for surgery in early-stage disease. Prophylactic cranial irradiation seems to improve outcomes in patients who have responded to initial therapy. This review addresses the practical aspects of staging and treatment of patients with limited-stage SCLC.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research